ACM
ZVRA icon

AIGH Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

AIGH Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000,000
Closed -$8.96M – 49
2025
Q4 		$8.96M Sell
1,000,000
-2,221,110
-69% -$21M 2.17% 15
2025
Q3 		$7.65M Buy
+3,221,110
New +$32.3M 2.16% 18
2024
Q3 		– Sell
-137,600
Closed -$674K – 46
2024
Q2 		$674K Buy
+137,600
New +$652K 0.21% 34

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AIGH Capital Management's ZVRA Position: Q1 2026 in Review

AIGH Capital Management opened a new position in Zevra Therapeutics (ZVRA) in Q1 2026: 1,200,000 shares worth $11.2M. The stake represents 1.53% of the portfolio and ranks #20 among its holdings. This is a return to the name: AIGH Capital Management previously reported a position in ZVRA as recently as Q3 2025.

AIGH Capital Management first reported a position in ZVRA in Q2 2024 and has held it in 6 quarters since. The position peaked at $11.7M in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • AIGH Capital Management held 1,200,000 shares of Zevra Therapeutics worth $11.2M as of Q1 2026.
  • Zevra Therapeutics was a new AIGH Capital Management position in Q1 2026.
  • Zevra Therapeutics made up 1.53% of AIGH Capital Management's portfolio in Q1 2026, its #20 holding.
  • AIGH Capital Management first reported a position in Zevra Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • AIGH Capital Management's Zevra Therapeutics position peaked at $11.7M in Q3 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on AIGH Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.